Drug Profile


Alternative Names: Galantamine Hydrobromide; Galanthamine; GP 37267; Nivalin; R 113675; Razadyne; Razadyne ER; Reminyl; Reminyl ER

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanochemia Pharmazeutika
  • Developer Janssen Pharmaceutical KK; Janssen-Cilag; Sanochemia Pharmazeutika
  • Class Alkaloids; Benzazepines; Nootropics; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease
  • Phase I/II Down syndrome
  • Discontinued Chronic fatigue syndrome; Delirium; Fibromyalgia; Mild cognitive impairment; Vascular dementia

Most Recent Events

  • 17 Dec 2016 Janssen-Cilag discontinues phase I/II trial in Down-syndrome (In children, In adolescents) in Belgium and Netherlands (EudraCT2006-003359-19) before December 2016
  • 15 Mar 2016 Biomarkers information updated
  • 05 Dec 2012 Efficacy data from a phase III trial in Alzheimer's disease released by Janssen Research and Development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top